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Two-hybridIntermediate ﬁlaments are cytoskeletal elements important for cell architecture. Recently it has been discovered
that intermediate ﬁlaments are highly dynamic and that they are fundamental for organelle positioning,
transport and function thus being an important regulatory component of membrane trafﬁc. We have identiﬁed,
using the yeast two-hybrid system, vimentin, a class III intermediate ﬁlament protein, as a Rab7a interacting
protein. Rab7a is a member of the Rab family of small GTPases and it controls vesicular membrane trafﬁc to
late endosomes and lysosomes. In addition, Rab7a is important for maturation of phagosomes and autophagic
vacuoles. We conﬁrmed the interaction in HeLa cells by co-immunoprecipitation and pull-down experiments,
and established that the interaction is direct using bacterially expressed recombinant proteins. Immunoﬂuores-
cence analysis on HeLa cells indicate that Rab7a-positive vesicles sometimes overlap with vimentin ﬁlaments.
Overexpression of Rab7a causes an increase in vimentin phosphorylation at different sites and causes redistribu-
tion of vimentin in the soluble fraction. Consistently, Rab7a silencing causes an increase of vimentin present in
the insoluble fraction (assembled). Also, expression of Charcot–Marie–Tooth 2B-causing Rab7a mutant proteins
induces vimentin phosphorylation and increases the amount of vimentin in the soluble fraction. Thus,
modulation of expression levels of Rab7a wt or expression of Rab7a mutant proteins changes the assembly of
vimentin and its phosphorylation state indicating that Rab7a is important for the regulation of vimentin function.
© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Intermediate ﬁlaments (IFs) are amajor element of the cytoskeleton
of animal cells although the less understood [1,2]. The IF protein family
comprises about 70 different, although structurally related, members
that are grouped in ﬁve different classes [1,2]. IF proteins are expressed
at different stages during development and differentiation and several
different IF proteins are expressed at the same time in a cell type
[1,2]. IFs are the primary determinants of cell architecture and are
assembled and organized in a highly dynamic way [2,3]. Recently,
it has been discovered that IFs are also important for organelle
positioning, organelle transport and organelle function [4].
Vimentin, the major intermediate ﬁlament protein of mesenchymal
cells, is highly conserved in vertebrates, with a variable expression
pattern during development and differentiation [5]. It has been
demonstrated that vimentin moves bi-directionally alongmicrotubulesemagglutinin; EGFP, Enhanced
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.
partment of Molecular Biosci-
-NC-ND license.using kinesin and dynein–dynactin [3]. Vimentin assembly and
functions are regulated by phosphorylation and indeed vimentin
shows a complex phosphorylation pattern with several kinases being
involved [5,6]. Different phosphorylation patterns of vimentin are
associated to different mitotic phases [5,6].
A number of studies have established that vimentin has many
distinct and complex functions and it seems to organize several
cellular processes as attachment, migration and signaling by controlling
the function of key proteins [5]. For instance, vimentin has a key role in
the migration of immune cells, in the regulation of membrane-
associated protein complexes, in the modulation of protein kinases
serving as a scaffold, and even in the regulation of DNA by, for instance,
sequestering transcription factors [5]. Also, beside regulating integrin
trafﬁcking, vimentin regulates integrin functions by constituting the
vimentin associated matrix adhesions that, in some cases, involve
even a direct interaction between vimentin and integrins [5,7,8].
Furthermore, vimentin plays an important role also in membrane traf-
ﬁc. Indeed, vimentin ﬁlaments are required for late endocytic trafﬁc,
for correct positioning of endosomes and lysosomes and for maturation
of autophagosomes [9,10].
Using the two-hybrid systemwe isolated vimentin as an interacting
partner of Rab7a, a small GTPase controlling late endosomal trafﬁc.
Unlike Rab7b, which is involved in the regulation of endosomes to
TGN transport [11,12], Rab7a is important for the biogenesis of
lysosomes, phagolysosomes and autolysosomes [13–16]. Rab7a exerts
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Rab-interacting lysosomal protein), which is important also for
multivesicular body biogenesis [17–20]. Mutations in the rab7a gene
cause a peripheral neuropathy, the Charcot–Marie–Tooth type 2b
(CMT2B), characterized by prominent sensory loss, muscle weakness,
muscle atrophy, recurrent infections and ulcers leading to amputations
[21–25]. In the nervous system Rab7a controls endosomal trafﬁcking
and signaling of nerve growth factor receptors [26,27], and mutant
Rab7a proteins causing CMT2B have altered nucleotides Koff, inhibit
neurite outgrowth and alter neurotrophin trafﬁcking and signaling
[28–33].
Our data indicate that Rab7a interacts directly with vimentin,
and that this interaction modulates vimentin phosphorylation and
assembly. Thus, we have discovered a new mechanism for vimentin
regulation. These data suggest that Rab7a could, through the interac-
tion with vimentin, be involved in the regulation of new cellular
processes.
2. Materials and methods
2.1. Cells and reagents
Restriction and modiﬁcation enzymes were from New England
Biolabs (Ipswich, MA). Chemicals and tissue culture reagents were
from Sigma-Aldrich (St. Louis, MO). HeLa cells were grown in
DMEM supplemented with 10% heat inactivated FBS, 2 mM
glutamine, 100 U/ml penicillin and 10 mg/ml streptomycin, in a
5% CO2 incubator at 37 °C.
2.2. Yeast two-hybrid assay
A Gal4-binding domain/Rab7a ΔC fusion construct in the pGBKT7
vector was used to screen a pretransformed normalized human
Matchmaker cDNA library (Clontech, # 638874) in order to identify
Rab7a interacting proteins using AH109 yeast cells [34–36].
Transformants were plated onto synthetic medium lacking His, Leu,
and Trp and clones were picked up after 5–6 days of incubation at
30 °C. From 2 × 106 primary transformants, 18 were encoding true
positive clones and two of them encoded vimentin. Speciﬁcity tests
were made transforming AH109 yeast cells with the pGBKT7 vector
or PGBKT7-RILP (as a negative controls) or the pGBKT7-Rab7a wt
constructs, and with the PGADT7-vimentin constructs. Clones
were then assayed for growth on selective medium and for
β-galactosidase activity using o-nitrophenyl-β-D-galactoside as a
substrate [34–36].
2.3. Plasmid construction
Rab7a constructs used in this study have been described
previously [28,31,37]. Myc-tagged vimentin was obtained from
OriGene (RC201546). Vimentin ORF was transferred using AsiSI and
MluI restriction enzymes to pCMV6-AN-HA (OriGene, PS100013)
to obtain a vector for the expression of HA-tagged vimentin.
Vimentin ORF was also ampliﬁed by PCR using the following
oligonucleotides: 5′-ACGCGGATCCATGTCCACCAGGTCCGTG-3′ and
5′-CCGGAATTCTTATTCAAGGTCATCGTGATGC-3′ and cloned in the
vector pGEX4T3 using the restriction enzymes BamHI and EcoRI
in order to obtain a plasmid for the bacterial expression of
GST-tagged vimentin. All the newly made constructs were se-
quenced veriﬁed.
2.4. Transfection and RNA interference
Transfection was performed using Metafectene Pro or Metafectene
Easy from Biontex (Karlsruhe, DE), as indicated by the manufacturer.
After 20 h of transfection cells were processed for immunoﬂuorescenceor biochemical assays. For RNA interference control RNA (sense se-
quence 5′-ACUUCGAGCGUGCAUGGCUTT-3′ and antisense sequence
5′-AGCCAUGCACGCUCGAAGUTT-3′) and Rab7a-1 siRNAs (sense
sequence 5′-GGAUGACCUCUAGGAAGAATT-3′ and antisense se-
quence 5′-UUCUUCCUAGAGGUCAUCCTT-3′) were purchased from
MWG-Biotech (Ebersberg, Germany). The Rab7a siRNAs were efﬁ-
cient in silencing Rab7a as mRNA levels were reduced of about 80%
and the Rab7a endogenous protein was not anymore detectable by
Western blot [28]. Brieﬂy, HeLa cells were plated 1 day before trans-
fection in 6 cm diameter tissue culture dishes, transfected with
siRNAs using Oligofectamine from Invitrogen (Milan, Italy) for
72 h, re-plated and left 48 h before performing further experiments.
2.5. Coimmunoprecipitation, pull-down and direct interaction experiments
For co-immunoprecipitation 25 μl of anti-HA resin (Ezview
Red Anti-HA Afﬁnity gel from Sigma-Aldrich) was used according
to the manufacturer instructions. Brieﬂy, cells were lysed with
RIPA buffer (R078 from Sigma-Aldrich) and lysates were incubated
with the anti-HA resin for 1 h at 4 °C on a rotating wheel.
Co-immunoprecipitation of endogenous proteins was performed
in HeLa cells using a crosslink immunoprecipitation kit (Pierce)
following manufacturer instructions. Brieﬂy, mouse anti-Rab7a
antibody (Sigma) or mouse IgG was crosslinked to a resin using
disuccinimidyl suberate (DSS) and incubated with pre-cleared
HeLa cell lysate. After washing and elution immunoprecipitates
were subjected to western blotting analysis using rabbit anti-Rab7a
and anti-vimentin antibodies.
Immunoprecipitated samples were then loaded on SDS-PAGE and
analyzed by Western blotting.
For pull-down His-tagged Rab7a wt and mutant proteins were
expressed and puriﬁed from Escherichia coli BL21 as previously
described [38]. 20 μg of each puriﬁed protein was bound to NiNTA
resin at 4 °C for 45 min. Then the resin was washed 3 times for
5 min with a washing solution (NaH2PO4 50 mM, NaCl 300 mM,
Imidazole 20 mM, pH 8.0) and incubated with the cellular lysate of
N2A cells at 4 °C for 1 h. After extensive washing pulled-down
samples were loaded on SDS-PAGE and analyzed byWestern blotting.
For direct interaction GST, GST-tagged and His-tagged proteins
were expressed in bacteria and afﬁnity puriﬁed as described [17,38].
His-tagged Rab7a wt was incubated alone or in combination with
GST or GST-tagged vimentin in PBS with 2 mM MgCl2 and GTP
0.8 mM for 1 h on a rotating wheel. Subsequently, samples were
subject to GST pull-down using a glutathione resin. Samples were
then subjected to SDS-PAGE and Western blotting.
2.6. Antibodies
Mouse monoclonal 9E10 anti-Myc (ab32) and rabbit polyclonal
anti-HA (ab9110) antibodies were from Abcam (Cambridge, UK),
rabbit polyclonal anti-Rab7a (R4779), mouse monoclonal anti-Rab7a
(R8779) and mouse monoclonal anti-tubulin (T5168) were from
Sigma-Aldrich (St. Louis, MO), while anti-vimentin (sc-6260) and
anti-vimentin phospho Ser38 (sc-16673) antibodies were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). The anti-vimentin
phospho Ser55 (ab22651) antibody was from Abcam (Cambridge,
UK). Primary antibodies were used at a 1:500–1:1000 unless otherwise
indicated. Secondary antibodies conjugated with ﬂuorochromes (used
at 1:500 dilution) or HRP (used at 1:5000 dilution) were from Invitrogen
(Milan, IT) or Santa Cruz Biotechnology (Santa Cruz, CA, USA).
2.7. Western blotting
Cells were lysed in RIPA buffer and lysates were loaded onto
SDS-PAGE. Separated proteins were transferred onto PVDF membrane
from Millipore (Milan, IT). When phosphorylation was monitored,
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(PhosphoSTOP, Roche). The ﬁlter was blocked in 5% milk in PBS for
30 min at room temperature, incubated with the appropriate prima-
ry antibody, washed in 5% milk in PBS and then incubated with a
secondary antibody conjugated with HRP (diluted 1:5000). Bands
were visualized using enhanced chemiluminescence's system from
GE (Milan, IT) or Western blotting Luminol Reagent from SantaCruz
Biotechnology (Santa Cruz, CA, USA).
2.8. Confocal immunoﬂuorescence microscopy
Cells grown on 11-mm round glass coverslips were permeabilized,
ﬁxed and incubated with primary and secondary antibodies as
described previously [39,40]. Cells were viewed with Zeiss LSM 510
confocal microscope.
2.9. Analysis of soluble vimentin/insoluble vimentin ratio
The method to analyze the soluble/insoluble ratio of vimentin has
been previously described [41–43]. Brieﬂy, cells were incubated at
4 °C for 30 min with phospho-buffer (NaCl 150 mM, Hepes 20 mM
pH 7.6, 1% Igepal, 10% glycerol) containing phosphatase inhibitors
(phosphatase inhibitor cocktail 1 from Sigma-Aldrich) and protease
inhibitors (Complete protease inhibitor cocktail, Roche), and then
scraped. Samples were then centrifuged at 20,000 g at 4 °C for
20 min. The supernatant (soluble fraction) was collected while the
pellet (insoluble fraction) was washed 3 times with 2 mM EDTA
in PBS1X, resuspended in Triton buffer (PBS 1×, 1% SDS, 0.1% Triton)
and then boiled for 10 min and sonicated. Soluble and insoluble
fractions were then separated by SDS-PAGE, transferred on
nitrocellulose membrane and probed with the appropriate antibodies.
Immunocomplexes were revealed by chemiluminescence. The ratio of
soluble/insoluble vimentin was determined by scanning densitometry
of immunoblots.
2.10. Quantiﬁcation and statistical analysis
Protein levels were quantiﬁed by densitometry using the ImageJ
software. The levels of vimentin were normalized against tubulin or
against Rab7a, and analyzed statistically using Dunnett ANOVA
post-hoc test. The analysis was based on the comparison of cells
expressing HA-tagged Rab7a mutant proteins and cells expressing
HA-tagged Rab7a or control cells as indicated.
3. Results
3.1. Rab7a interacts directly with vimentin
A yeast two-hybrid screenwas used to identify proteins that interact
with Rab7a. A Gal4-binding domain/Rab7a fusion construct was made
in pGBKT7 vector and used to screen a human normalized universal
cDNA library made from a collection of adult tissues, encoding proteins
as C-terminal fusionswith the transcriptional activation domain of Gal4
in the pGADT7Rec vector. From 2 × 106 primary transformants, 18
were encoding true positives that did not activate transcription in the
presence of a non-speciﬁc test bait. Most of the clones encoded RILP
while two transformants encoded the entire vimentin. The interaction
was revealed by the growth of yeast cells expressing Rab7a wt and
vimentin on synthetic medium lacking histidine (Fig. 1A). In the
two-hybrid system the interactionwas speciﬁc as yeast cells expressing
vimentin alone were not able to grow without histidine (Fig. 1A).
Moreover, vimentin was found to interact with Rab9, as previously
published [43], but not with Ra7b, thus conﬁrming that Rab7a and
Rab7b are working on different steps of transport and interact with
different effector proteins [44]. These results were conﬁrmed using
the other reporter gene, β-galactosidase (Fig. 1B). Furthermore, in thetwo-hybrid system vimentin was able to interact also with Rab7a
mutant proteins such as the dominant negative T22N, the constitutively
active Q67L and the CMT2B-causing mutants L129F, K157N, N161T and
V162M (Fig. 1A–B).
To verify the results obtained with the two-hybrid screen we
investigated whether Rab7a was able to pull down vimentin from
cell extracts. We puriﬁed His-tagged Rab7a from bacteria and incu-
bated it with total extracts of HeLa cells overexpressing HA-tagged
vimentin. As shown in Fig. 1C, His-tagged Rab7a pulled down
HA-vimentin from total cell extracts, thus conﬁrming that the two
proteins are present in the same complex. Subsequently, to check
if the interaction was direct, we puriﬁed bacterially expressed
GST-tagged vimentin and His-tagged Rab7a, we incubated them
together and then we precipitated GST-tagged vimentin using the
glutathione resin. Western blot analysis of the precipitated proteins
revealed that His-Rab7a was able to bind to GST-vimentin (Fig. 1D).
No binding of His-Rab7a to the resin alone or to the GST protein
was detected (Fig. 1D). The binding between endogenous Rab7a and
vimentin was also demonstrated (Fig. 1E) thus conﬁrming the
physiological signiﬁcance of this interaction,
Altogether these data demonstrate that Rab7a interacts directly
with vimentin.3.2. Differential interaction of Rab7a mutant proteins with vimentin
Having established that Rab7a interacts directly with vimentin we
checked, using co-immunoprecipitation and pull-down, the ability to
interact of the different Rab7a mutant proteins with vimentin. In
particular, we used the dominant negative T22N mutant, the consti-
tutively active Q67L mutant and the CMT2b-causing Rab7a mutants
L129F, K157N, N161T and V162M.
Interestingly, Rab7a wt and mutant proteins were all able to
co-immunoprecipitate endogenous vimentin, thus again proving the
interaction between Rab7a and vimentin, but to different extent.
Indeed, more vimentin was co-immunoprecipitated with the four
CMT2b-causing mutant proteins (Fig. 2A). Quantiﬁcation of three
independent experiments revealed that these mutants were able to
co-immunoprecipitate about 3 fold more efﬁciently endogenous
vimentin compared to Rab7a wt (Fig. 2B). Similar results were
obtained using bacterially puriﬁed His-tagged Rab7a wt and mutant
proteins, in order to pull-down endogenous vimentin from HeLa
total extracts (Fig. 2C–D). Indeed, CMT2B-causing Rab7a mutant
proteins were able to pull-down vimentin about 2 fold more efﬁcient-
ly than Rab7a wt (Fig. 2D).
These data indicate that CMT2B-causing Rab7a mutant proteins
interact more strongly with vimentin.3.3. Intracellular localization of Rab7a wt and mutant proteins with
vimentin ﬁlaments
To investigate a possible role of this interaction we decided to
analyze the intracellular localization of Rab7a and vimentin in HeLa
cells. Initially, we overexpressed in HeLa cells GFP-tagged Rab7a wt
and examined its distribution using a speciﬁc antibody against
vimentin. Immunoﬂuorescence analysis revealed that there was
some, although extremely limited, colocalization of Rab7a with
vimentin (Fig. 3A–B). In particular, vesicles bearing Rab7a showed
regions of colocalization with vimentin ﬁlaments and, sometimes,
vesicles were surrounded by vimentin ﬁlaments (Fig. 3A–B). Further-
more, Rab7a-bearing vesicles were seen laying over vimentin
ﬁlaments (Fig. 3A–B). Similar results were obtained by expressing
CMT-2b causing Rab7a mutants (Fig. 3C–F). Immunoﬂuorescence
analysis on endogenous proteins revealed a similar distribution
pattern (Fig. 3G–H).
Fig. 1. Rab7a interacts directly with vimentin. AH109 yeast cells were co-transformed with pGADT7-vimentin and pGBKT7, PGBKT7-Rab7b, PGBKT7-Rab9 or pGBKT7-Rab7a wt or
mutant constructs. (A) Double transformants were plated on WL and HWL synthetic medium and grown at 30 °C for two days. (B) The β-galactosidase activity of double
transformants was measured using o-nitrophenyl-β-D-galactoside as substrate as detailed in Materials and methods. Activities are measured as arbitrary relative units and repre-
sent mean ± s.d. values of 6 independent transformants from three independent experiments. (C) NiNTA resin alone or together with puriﬁed His-Rab7 was incubated with total
extracts of HeLa cells overexpressing HA-vimentin. After afﬁnity chromatography proteins were subjected to Western blot analysis using anti-HA and anti-Rab7a antibodies. (D)
Glutathione resin alone or together with puriﬁed GST or GST-vimentin was incubated with puriﬁed His-Rab7a. After afﬁnity chromatography proteins were subjected to Western
blot analysis using anti-GST and anti-Rab7a antibodies. (E) Total extracts of HeLa cells and immunoprecipitates obtained with no antibodies (no ab), with mouse anti-Rab7a and
with mouse IgG, as indicated, were subjected to WB analysis using rabbit anti-Rab7a and rabbit anti-vimentin antibodies.
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ratio
To further investigate the effect of Rab7a on vimentin we exam-
ined whether the total amount of vimentin changed after modulation
of Rab7a expression in order to establish if Rab7 regulates vimentin
expression, stability or degradation (Fig. 4A,B). Expression or silenc-
ing of Rab7a did not change the amount of vimentin mRNA, as judged
by real time PCR (data not shown), nor the amount of vimentin pro-
tein suggesting that Rab7a does not inﬂuence vimentin expression or
degradation (Fig. 4A, B). No differences in the amount of total
vimentin were observed also when Rab7a mutant proteins were
expressed (Fig. 4A).
Subsequently, we decided to determine whether Rab7a inﬂuenced
vimentin assembly/disassembly. Vimentin is present in cells as
soluble precursors that can be assembled in ﬁlaments that are highly
insoluble. Thus, we silenced Rab7a in HeLa cells, and then we
analyzed the amount of vimentin present in the soluble and insoluble
fractions. Interestingly, Rab7a-depleted cells showed an increase of
vimentin in the insoluble fraction (Fig. 4C). Consistently, in these
cells the amount of vimentin in the soluble fraction was decreased
(Fig. 4C). Quantiﬁcation of four independent experiments indicatedthat these differences were statistically signiﬁcant (Fig. 4D). Then
we measured the amount of vimentin present in the soluble fraction
upon overexpression of Rab7a wt. In cells overexpressing Rab7a wt
the amount of vimentin in the soluble fraction increased signiﬁcantly
(Fig. 4E–F). Furthermore, overexpression of CMT2B-causing Rab7a
mutants caused a strong increase of soluble vimentin (Fig. 4E–F).
These data suggest that Rab7a is able to regulate vimentin assem-
bly and disassembly and that CMT2B-causing Rab7a mutant proteins
could induce vimentin disassembly.
3.5. Modulation of Rab7a expression changes the phosphorylation pat-
tern of vimentin
Vimentin dynamics are regulated by phosphorylation. Site-speciﬁc
phosphorylation induces disassembly of vimentin ﬁlaments, and the
increase of phosphorylation accompanies vimentin ﬁlament reorgani-
zation in vivo [45]. Vimentin is phosphorylated by different protein
kinases at several sites. In order to establish if Rab7a regulates vimentin
assembly by affecting vimentin phosphorylation, we used speciﬁc
antibodies against phospho-vimentin at positions Ser-38 and Ser-55
on total extracts of HeLa cells overexpressing HA-Rab7a wt and
mutant proteins. Notably, Rab7a overexpression caused an increased
Fig. 2. CMT2B-causing Rab7a mutant proteins show altered binding to vimentin. (A) HA-tagged Rab7a wt and mutant proteins were expressed in HeLa cells and
immunoprecipitated using an anti-HA resin. Immunoprecipitates were subjected to Western blot analysis using anti-vimentin and anti-HA antibodies. (B) Quantiﬁcation of four
independent co-immunoprecipitation experiments. Intensities of the bands were quantiﬁed by densitometry, normalized against the amount of the Rab7a protein expressed.
Values are mean ± s.d. (C) Puriﬁed His-tagged Rab7a wt and mutant proteins, as indicated, were incubated with total extracts of HeLa cells. Precipitated proteins after afﬁnity chro-
matography with NiNTA resin were loaded on SDS-PAGE and subjected to Western blot analysis using anti-vimentin and anti-Rab7a antibodies. (D) Quantiﬁcation of four indepen-
dent pull-down experiments. Intensities of the bands were quantiﬁed by densitometry and normalized against the amount of the Rab7a protein. Values are mean ± s.d. Values
obtained expressing disease-causing Rab7a mutant proteins were found to be signiﬁcantly different from the values obtained in cells expressing Rab7a wt (*p b 0.05, **p b 0.01).
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(Fig. 5A–D). Importantly, this increase was stronger when CMT2B-
causing Rab7a mutants were expressed (Fig. 5A–D). Consistently,
phosphorylation at these sites diminished in Rab7a-silenced cells
(Fig. 6A,B). Importantly, phosphorylation levels at Ser-38 and Ser-55
were increased by overexpression of HA-tagged Rab7a wt in
Rab7a-silenced cells, thus excluding off-target effects (Fig. 6C).
These data indicate that Rab7a regulates vimentin assembly trig-
gering phosphorylation of vimentin at two different sites, and that
disease-causing Rab7a mutant proteins induce stronger vimentin
phosphorylation.
3.6. Rab7 interacts with soluble and ﬁlamentous vimentin
The interaction between the bacterially expressed Rab7a and
vimentin proteins (Fig. 1D) indicates that Rab7 is able to interact
with unphosphorylated vimentin. In order to establish if Rab7a is
able to interact also with phosphorylated forms of vimentin we
immunoprecipitated HA-tagged Rab7a wt and Rab7a V162M
from total extracts of transfected HeLa cells. Both proteins were
able to co-immunoprecipitate Ser38 phospho-vimentin and Ser55
phospho-vimentin (Fig. 7A) thus indicating that Rab7a is able to
interact also with vimentin phosphorylated at positions 38 and 55.
Western blot analysis on total extracts conﬁrmed that, as previously
published [46,47], Ser38 and Ser55 phospho-vimentins are present
only in the soluble fraction (Fig. 7B). Thus, in order to establish if
Rab7 was binding only to soluble or also to ﬁlamentous vimentin
we separated soluble and insoluble fractions of HA-tagged Rab7a wt
and Rab7a V162M expressing HeLa cells and, subsequently, we did a
co-immunoprecipitation experiment (Fig. 7C). Rab7a wt and Rab7aV162M were able to co-immunoprecipitate vimentin from both
soluble and insoluble fractions while, as expected, Ser38 and Ser55
phospho-vimentins were immunoprecipitated only from the soluble
fraction (Fig. 7C).
These data indicate that Rab7 is able to interact with soluble and
ﬁlamentous vimentin and also with the S38 and S55 phosphorylated
forms.
4. Discussion
Vimentin is a key cytoskeletal protein that, through its highly
dynamic disassembly/assembly and spatial reorganization, partici-
pates in adhesion, migration survival, membrane trafﬁcking and cell
signaling processes [48].
Here, we demonstrated for the ﬁrst time that the small GTPase
Rab7a interacts directly with vimentin and regulates its assembly.
Indeed, overexpression of Rab7a increases the soluble/insoluble
vimentin ratio raising the pool of free, disassembled and phosphory-
lated vimentin that can be used to reorganize vimentin ﬁlaments
(Fig. 8). Consistently, in Rab7a-depleted cells vimentin soluble/insol-
uble ratio is decreased indicating that more vimentin is present in its
ﬁlamentous form and less is available for ﬁlament reorganization
(Figs. 4–6). In addition, we demonstrated that overexpression of
Rab7a wt and mutant proteins increases phosphorylation of Ser38
and Ser55 amino acids (Fig. 5) suggesting that Rab7a controls, direct-
ly or indirectly, vimentin phosphorylation. Thus we report for the ﬁrst
time the discovery of a new regulatory mechanism for vimentin
ﬁlament organization mediated by the small GTPase Rab7a.
Both dominant negative and active mutants interact with vimentin
having similar effects. This fact, in contrast with the proposed role of
Fig. 3. Intracellular localization of Rab7a and vimentin ﬁlaments. HeLa cells overexpressing GFP-tagged Rab7a wt (A–B) or L129F (C), K157N (D), N161T (E) V162M and (F) mutant
proteins were subjected to immunoﬂuorescence analysis using an anti-vimentin antibody followed by a Cy3 secondary antibody. (G–H) Hela cells were subjected to immunoﬂu-
orescence analysis using anti-Rab7a and anti-vimentin antibodies followed by Cy2 and a Cy3 conjugated secondary antibodies, respectively. The images represent
maximum-intensity projections of Z stacks. Bar = 10 μm.
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Rab proteins. For instance, both dominant negative and constitutively
active Rab17 mutants stimulate transcytosis and apical recycling
[49]. Also, both forms of Rab10 and Rab21 exhibit similar effect on
lipid droplet size [50], and HOPS complex seems to work equally well
with GDP- and GTP-bound Ypt7, the yeast counterpart of mammalian
Rab7 [51]. Furthermore, in plants both forms of Rab11b negatively
impact pollen tube growth properties and male fertility [52]. A possible
explanation is that a proper ratio of inactive (GDP-bound) and active
(GTP-bound) forms of the protein is necessary for the correct regulation
of downstream processes. In addition, in the case of Rab7 and vimentin,
although both kinds of mutants show similar effects, GTP-bound
mutants seem to display higher binding to vimentin and affect moreits assembly leading to suppose that small differences in vitro may
have a larger impact in vivo.
The discovery of the interaction between Rab7 and vimentin is of
importance for several reasons.
First of all, recent evidence indicates that intermediate ﬁlaments
are important for organelle positioning, movement and function
[4]. In particular, vimentin ﬁlaments have a fundamental role in
endocytic membrane trafﬁc, being required for correct positioning
of endosomes and lysosomes, for transport to late endosomes and
lysosomes, and for maturation of autophagosomes [9,10]. As these
functions are shared with Rab7a, it is tempting to speculate that
Rab7a and vimentin act in concert to regulate some or all of these
processes. In support of this hypothesis, our data demonstrate a
Fig. 4.Modulation of Rab7a expression alters vimentin ﬁlament organization. (A) Total extract of Hela cells (NT) or of HeLa cells expressing HA-tagged Rab7a wt and mutant pro-
teins as indicated were subjected to Western blot analysis with anti-vimentin, anti tubulin and anti-HA antibodies. Total extracts (B) or soluble and insoluble extracts (C) of Hela
cells treated with control RNA (scr) or with Rab7a siRNA as indicated were subjected to Western blot analysis using anti-Rab7a, anti-tubulin and anti-vimentin antibodies. (D)
Quantiﬁcation of soluble and insoluble vimentins in Rab7a-depleted HeLa cells. The values represent the mean ± s.d. of four independent experiments. The intensities were quan-
tiﬁed by densitometry, normalized against the amount of tubulin and plotted relatively to the intensities obtained in cells transfected with control RNA (scr). Values obtained in
Rab7a-depleted cells were found to be signiﬁcantly different from the values obtained in control (scr) cells (**p b 0.01, ***p b 0.001). (E) Soluble extracts of HeLa cells
overexpressing HA-tagged Rab7a wt and mutant proteins (as indicated) were subjected to Western blot analysis using anti-vimentin, anti-tubulin and anti-HA antibodies. (F)
Quantiﬁcation of soluble vimentin in HeLa cells transfected with HA-Rab7a wt and mutant proteins. The values represent the mean ± s.d. of four independent experiments. The
intensities were quantiﬁed by densitometry, normalized against the amount of tubulin and plotted relatively to the intensities obtained in control cells (NT). Values obtained in
cells overexpressing Rab7a wt or expressing disease-causing Rab7a mutant proteins were found to be signiﬁcantly different from the values obtained in control (NT) cells
(*p b 0.05, **p b 0.01).
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of membrane trafﬁc, and vimentin, strongly supporting the idea that
intermediate ﬁlaments have a key role in membrane trafﬁc, as
previously suggested [4]. Notably, also another Rab GTPase localized
to late endosomes, Rab9, has been found to interact with vimentin
and this interaction is altered by lipid accumulation in Niemann–
Pick type C1 disease suggesting a concerted role of Rab9 and vimentin
in the regulation of intracellular lipid transport [43].
Second, it has been demonstrated that neurons possess an
evolutionary conserved damage-response program that recapitulatesthe developmental stages required for neuronal differentiation (as
neurite outgrowth and synapses formation) and expression of vimentin
is part of this program [53]. Indeed, vimentin is normally not expressed
or expressed at very low levels in mature neurons, but its expression is
induced during axonal regeneration after injury [54]. As an example,
neuronal expression of vimentin has been demonstrated in Alzheimer's
disease as part of damage-response mechanism [53]. Furthermore, in
neurons of teleost ﬁsh, which show a much higher regenerative ability
compared to mammals, a strong up-regulation of vimentin has been
reported during regeneration [55].
Fig. 5. Rab7a overexpression induces vimentin phosphorylation. Total extracts of control HeLa cells (NT) or HeLa cells transfected with HA-tagged Rab7a wt and mutant proteins, as
indicated, were subjected to Western blot analysis using anti-phospho-vimentin Ser38 (A) or Ser55 (C), anti-tubulin and anti-HA antibodies. (B, D) Quantiﬁcation of phosphory-
lated vimentin Ser38 (B) or Ser55 (D) in cells expressing Rab7a wt and mutant proteins. Values represent the mean mean ± s.d. of four independent experiments. Intensities of the
bands were quantiﬁed by densitometry, normalized against the amount of tubulin and plotted relatively to the values obtained in control HeLa cells (NT). Values obtained in cells
expressing disease-causing Rab7a mutant proteins were found to be signiﬁcantly different from the values obtained in control (NT) cells (*p b 0.05, **p b 0.01).
Fig. 6. Vimentin phosphorylation is decreased in Rab7a-silenced cells. (A–B) Total ex-
tracts of Hela cells treated with control RNA (scr) or with Rab7a siRNA, as indicated,
were subjected to Western blot analysis using anti-phospho Ser38 (A) or Ser55 (B),
anti-tubulin and anti-Rab7a. (C) Total extracts of Hela cells treated with control RNA
(scr) or with Rab7a siRNA and transfected with HA-Rab7a, as indicated, were subjected
to Western blot analysis using anti-phospho Ser38 and anti-phospho Ser55 vimentins,
anti-Rab7a, anti-HA and anti-α-tubulin antibodies.
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[22,24,25,56]. Others and we have demonstrated that these
mutations alter neurite outgrowth and neurotrophin trafﬁcking and
signaling [30,32,33]. As the onset of CMT2B is in the second-third
decade of life and thus development is not affected, these mutant
proteins could, besides being responsible for neuronal degeneration,
also affect axonal regeneration. Hence, altered interaction of the
CMT2B-causing Rab7a mutant proteins with vimentin could result
in variations of vimentin distribution and function that might in
turn, impair the damage-response program, compromising axonal
regeneration. In addition vimentin has been found to co-assemble
with the light neuroﬁlament and the corresponding NEFL gene is
mutated in several forms of the CMT disease suggesting that
alterations of vimentin cytoskeleton could affect also neuroﬁlament
organization [57–61].
Third, vimentin is an important factor for tumorigenesis. Tissues
going through “epithelial tomesenchymal transition” express vimentin,
and vimentin seems to contribute heavily to the acquisition of tumori-
genic and metastatic properties to the point that it has been
demonstrated that vimentin expression correlates with poor outcome
for epithelial cancers [48,62–66]. In addition, in tumor cells the amount
of free soluble vimentin is signiﬁcantly higher than in normal cells
suggesting that vimentin could be a novel target for therapeutical
tools against cancer cells [48,67]. Rab proteins are also involved in signal
transduction and in particular Rab7a has been demonstrated to prevent
growth factor-independent survival and to control EGFR endocytic
trafﬁcking, whose alterations have been linked to tumorigenesis
[68–71]. The discovery of a tight relationship between Rab7a and
Fig. 7. Rab7a is able to interact with the phosphorylated form of vimentin. (A) Total ex-
tract of HeLa cells expressing HA-tagged Rab7a wt or Rab7a V162M were subjected to
immunoprecipitation using anti-HA resin. Western blot analysis of immunoprecipi-
tates was made using anti-HA, anti-phospho-vimentins Ser55 and Ser 38. (B) Soluble
and insoluble fractions of Hela cells expressing HA-tagged Rab7a wt or Rab7a V162M
were subjected to Western blot analysis using anti-phospho-vimentins Ser55 and Ser
38. (C) Soluble and insoluble fractions of HeLa cells expressing HA-tagged Rab7a wt
or Rab7a V162M were immunoprecipitated using anti-HA resin. Immunoprecipitates
were subjected to WB analysis using anti-phospho-vimentins Ser38 and Ser55,
anti-vimentin and anti-HA antibodies.
Fig. 8. A model for the role of Rab7a in vimentin assembly. Rab7a induces vimentin
phosphorylation at different sites and this, in turn, causes vimentin disassembly.
Rab7a is able to bind both to the soluble and ﬁlamentous forms of vimentin.
1291L. Cogli et al. / Biochimica et Biophysica Acta 1833 (2013) 1283–1293vimentin supports the notion that Rab7a is implicated in tumorigenesis
and indicates that modulation of Rab7a function could be useful to alter
vimentin assembly and thus might represent a targeted therapy for
epithelial tumors.
In addition, it has recently been reported that endocytosis is
important for neuronal migration and a number of endocytic Rab
have been shown to participate in this process [72]. For instance,
inhibition of Rab7a mediated transport to endocytic degradative
compartments affects the ﬁnal phase of neuronal migration and
maturation [72]. It is tempting to speculate that Rab7a could act in
this process by regulating vimentin.5. Conclusions
The ﬁndings that Rab7a interacts with vimentin and controls
vimentin phosphorylation state and assembly suggest a close connec-
tion between membrane trafﬁc regulatory proteins and intermediate
ﬁlaments. Furthermore, the discovery of the interaction betweenRab7a and vimentin opens new scenarios on the cellular role of Rab7
that will have to be further investigated.
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